Erlotinib and dacomitinib are inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and are used to treat non-small cell lung cancer, pancreatic cancer, and several other cancer types. Here, EGFR is linked to pancreatic neoplasm.